• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

COVID-19 Attitude Check: Worry About Long COVID-19, Confidence in Vaccines and Antivirals | Managed Healthcare Executive® State of the Industry Survey

Publication
Article
MHE PublicationMHE January 2023
Volume 33
Issue 1

Most of the respondents believe vaccination and antivirals have turned COVID-19 into manageable disease, but there is concern about long COVID-19.

Year 3 of the COVID-19 pandemic is upon us. The U.S. Centers for Disease Control and Prevention (CDC) data tracker shows that while cases are declining, just under 4,000 deaths are occurring weekly. Only about 15% of the population is up to date with vaccination boosters, according to the CDC, and NPR reported today that the FDA is considering a major shift in the COVID-19 vaccination strategy that would position COVID-19 shots like flu shots, so the would be annual and tailored to the circulating variants.

These and other facts fit with the views of COVID-19 reflected in the Managed Health Executive® annual State of the Industry survey, which was conducted in late November and early December 2022.

Almost half (47%) of the 450 respondents agreed that COVID-19 is endemic and just over (54%) agreed that vaccines and antivirals have made it a manageable disease. A large proportion but not a majority (40%) agreed that new variants ill circulate but that the current vaccines will protect against them.

Many (46%) of the respondents said they wear a mask in indoors and more than half (54%) said they avoid crowded indoor places, such as restaurants, because of COVID-19. Only a small group (16%) said they had stopped masking, and a very small group (5%) had not been vaccinated.

Even as the federal government is preparing to step away from buying COVID-19 vaccine directly and shifting that expense to insurers and other payers, the vast majority (90%) of the respondents to the annual State of the Industry survey indicated they favor the government continuing to buy the vaccine and make it free to the public.

Most (53%) of the respondents indicated that they see long COVID-19 as a major public health issue and almost many (47%) indicated they are worried about getting long COVID-19 themselves

On the other hand, a large group (56%) indicated agreement that vaccination and COVID-19 treatments have significantly reduced the risk of long COVID-19.

Related Videos
Video 2 - "Bridging Care Gaps with Prescription Digital Therapeutics"
Video 1 - "Overview of Prescription Digital Therapeutics and Impact on Clinical Practice"
Video 4 - "Payer Challenges in Evaluating Digital Therapeutics"
Video 3 - "Industry Collaboration in Shaping Digital Therapeutics Standards"
Video 6 - "Key Takeaways and Unmet Needs in Diabetes Treatment"
Video 5 - "Allocation of Investment and Value-Based Arrangements in Diabetes Care "
Video 4 - "Diabetes Prevention and Reducing Disparities Across Populations"
Video 3 - "Integrating CGMs into Diabetes Treatment Programs"
Related Content
© 2024 MJH Life Sciences

All rights reserved.